Status:
ENROLLING_BY_INVITATION
Clinical Triage and Treatment of Atypical Glandular Cells (AGC) Detected in Screening
Lead Sponsor:
Karolinska Institutet
Collaborating Sponsors:
Regional Cancer Centre Stockholm Gotland
Karolinska University Hospital
Conditions:
Uterine Cervical Cancer
Eligibility:
FEMALE
23-64 years
Phase:
NA
Brief Summary
The risk of cervical cancer after diagnosis with atypical glandular cells (AGC) detected by screening is elevated for 15 years after discovery. The current recommendation is that when AGC is detected ...
Detailed Description
Evidence from a nationwide cohort study demonstrated that the risk of cervical cancer following a diagnosis of AGC detected in screening was elevated for 15 years, particularly the risk of adenocarcin...
Eligibility Criteria
Inclusion
- give informed consent
- Women diagnosed with AGC (atypical glandular cells, M69720) and HPV 16/18 positive, detected in cervical screening.
Exclusion
- Do not give informed consent
- HPV negative or none-HPV16/18 positive
Key Trial Info
Start Date :
January 27 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2029
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT05231993
Start Date
January 27 2022
End Date
December 1 2029
Last Update
March 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska University Hospital
Stockholm, Sweden